Search

Roivant Sciences Ltd

Suletud

SektorTervishoid

41 0.44

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.36

Max

41.58

Põhinäitajad

By Trading Economics

Sissetulek

-646M

-291M

Müük

-1.1M

1.4M

Aktsiakasum

-0.45

Kasumimarginaal

-20,152.982

Töötajad

721

EBITDA

-743M

-288M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+11.62% upside

Turustatistika

By TradingEconomics

Turukapital

1.2B

25B

Eelmine avamishind

40.56

Eelmine sulgemishind

41

Uudiste sentiment

By Acuity

50%

50%

112 / 339 Pingereas Healthcare

Roivant Sciences Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. sept 2026, 20:13 UTC

Shares of Roivant Sciences are lower in after-market hours, reflecting a notable decline since Monday's close, despite remaining above the 20-day moving average.

11. sept 2026, 20:13 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, amid broader market concerns over potential Federal Reserve interest rate hikes following recent inflation data.

10. sept 2026, 23:31 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

9. sept 2026, 23:06 UTC

Roivant Sciences Ltd shares are higher in after-market hours, maintaining a narrow trading range since Wednesday's close and staying above the 20-day moving average.

8. sept 2026, 23:06 UTC

Event
News

Roivant Sciences Ltd shares are lower in after-market hours despite positive Phase 2 trial results for mosliciguat targeting pulmonary hypertension.

4. sept 2026, 22:51 UTC

Correlated Moves

Roivant Sciences Ltd shares are lower in after-market trading, reflecting broader market declines and negative sentiment in the biotech sector.

2. sept 2026, 20:08 UTC

Roivant Sciences Ltd shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

1. sept 2026, 19:36 UTC

Roivant Sciences Ltd is trading lower amid broader market sentiment and rising oil prices. The stock remains below its 20-day moving average.

31. aug 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-hours trading, showing modest gains since Monday's close amid rising oil prices and geopolitical tensions.

29. aug 2026, 00:01 UTC

Roivant Sciences Ltd shares are higher in after-market hours, reflecting notable activity despite a retracement from earlier gains. No specific news was identified.

28. aug 2026, 23:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Friday's close, despite no specific news identified.

27. aug 2026, 23:02 UTC

Roivant Sciences Ltd. shares are higher in after-market trading, remaining above the 20-day moving average despite earlier fluctuations during the session.

26. aug 2026, 22:41 UTC

Roivant Sciences Ltd is trading higher in after-market hours, reflecting broader market gains. The asset has closed higher for three consecutive sessions.

25. aug 2026, 23:16 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, continuing a steady decline since Tuesday's close, though still above the 20-day moving average.

24. aug 2026, 23:01 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, retracing from an earlier session high while remaining above the 20-day moving average.

21. aug 2026, 19:31 UTC

Roivant Sciences is declining in Friday's session, with no specific news identified. The stock has seen unusually high trading volume today.

20. aug 2026, 23:21 UTC

Roivant Sciences Ltd. shares are lower in after-market trading amid broader market pressures, including rising bond yields and concerns over high borrowing costs.

19. aug 2026, 23:26 UTC

Roivant Sciences Ltd is seeing upward momentum in after-market trading, recovering from a prior dip and nearing the upper end of its one-month trading range.

18. aug 2026, 23:01 UTC

Roivant Sciences Ltd shares are lower in after-market trading, declining notably after Tuesday's close amid rising U.S. Treasury yields and inflation concerns.

17. aug 2026, 19:36 UTC

Roivant Sciences shares are roughly flat amid broader market declines. The bond market faces upward pressure on yields due to inflation concerns.

14. aug 2026, 19:26 UTC

Roivant Sciences Ltd. remains near unchanged amid no specific news, fluctuating around flat levels during Friday's session. It is 4.29% above its 20-day moving average.

13. aug 2026, 19:36 UTC

Roivant Sciences Ltd is trading modestly higher amid broader market dynamics. Initial jobless claims rose above expectations, indicating potential softness in the labor market.

12. aug 2026, 22:11 UTC

Roivant Sciences shares are higher in after-market trading, driven by a positive market reaction to the July Consumer Price Index report.

11. aug 2026, 21:01 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing recent declines amid broader market volatility linked to U.S.-Iran relations.

10. aug 2026, 23:02 UTC

Roivant Sciences Ltd shares are higher in after-market hours, trading above their 20-day moving average and near the upper end of their one-month range.

7. aug 2026, 20:02 UTC

Event
News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

6. aug 2026, 20:03 UTC

News
Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

5. aug 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

4. aug 2026, 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3. aug 2026, 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

Võrdlus sarnastega

Hinnamuutus

Roivant Sciences Ltd Prognoos

Hinnasiht

By TipRanks

11.62% tõus

12 kuu keskmine prognoos

Keskmine 45.563 USD  11.62%

Kõrge 55 USD

Madal 37.5 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Roivant Sciences Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

112 / 339 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat